Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Joseph Brierre

Medical Oncology Lafayette, LA Medical Doctor

NPI 1316918394 CMS profile 332165

4809 Ambassador Caffery Pkwy, Suite 110, Lafayette, LA 70508

Open in the dashboard

General payments

$4,886

293 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Joseph Brierre of Lafayette, LA is reported in the CMS Open Payments database as having received $4,886 across 293 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 51st percentile of Medical Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $854 43
2024 General $729 38
2023 General $545 30
2022 General $584 33
2021 General $364 23
2020 General $366 20
2019 General $1,444 106

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joseph Brierre
  • Medical Oncology median
  • Middle half of Medical Oncology
  • National median

In program year 2025, general payments to Joseph Brierre were reported at $854. Among 3,316 Medical Oncology profiles paid that year, the median was $1,128 and the middle half received between $147 and $5,675.

Show as a table
Year Joseph Brierre Medical Oncology median Middle half National median
2019 $1,444 $968 $140–$6,658 $163
2020 $366 $747 $102–$5,891 $114
2021 $364 $430 $50–$4,098 $132
2022 $584 $812 $127–$4,907 $149
2023 $545 $957 $144–$5,248 $160
2024 $729 $1,042 $149–$5,650 $164
2025 $854 $1,128 $147–$5,675 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $492 37 payments
  2. Merck Sharp & Dohme Corporation $449 26 payments
  3. E.R. Squibb & Sons, L.L.C. $367 29 payments
  4. Novartis Pharmaceuticals Corporation $335 16 payments
  5. Amgen Inc. $291 12 payments
  6. Celgene Corporation $282 16 payments
  7. AstraZeneca Pharmaceuticals LP $245 16 payments
  8. Janssen Biotech, Inc. $234 12 payments
  9. Gilead Sciences, Inc. $182 11 payments
  10. Daiichi Sankyo Inc. $137 6 payments
  11. Other $1,872 112 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,712 286 payments
  2. Education $174 7 payments
Products named General payments · program years 2019–2025
  1. KEYTRUDA $449 26 payments
  2. IBRANCE $199 13 payments
  3. XTANDI $153 13 payments
  4. BRUKINSA $140 8 payments
  5. LYNPARZA $125 7 payments
  6. KISQALI $122 5 payments
  7. XGEVA $122 6 payments
  8. Lenvima $118 6 payments
  9. BOSULIF $118 9 payments
  10. OPDIVO $118 10 payments
  11. Other $4,281 262 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

345

Median for Hematology-Oncology: 604

Drug cost

$14,058

Median for Hematology-Oncology: $1,306,514

Branded share of claims

32.2%

Median for Hematology-Oncology: 31.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 12 $7,088
Fentanyl Generic 14 $2,128
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 70 $1,497
Letrozole Generic 65 $954
Anastrozole Generic 22 $518
Dexamethasone Generic 30 $474
Sucralfate Generic 11 $408
Ondansetron Odt Ondansetron Brand 17 $281
Valacyclovir Valacyclovir Hcl Brand 12 $247
Prochlorperazine Maleate Generic 13 $142

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 8,746 Part D prescribers listed as Hematology-Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$78,975

Medicare's payments for the services billed

Medicare patients

461

Average age 76

Services billed

1,271

293 women, 168 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 61%
Arthritis 41%
Ischemic heart disease 34%
Diabetes 31%
Atrial fibrillation 25%
Chronic kidney disease 24%
Osteoporosis 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 36 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENHERTU
$61 — —
OGSIVEO
$44 — —
KEYTRUDA
$41 — —
REBLOZYL
$39 — —
CARVYKTI
$27 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 36 with Patron

Records

293 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record